Skip to content

Multimodal AI for Predicting Survival Risk in critically ill children: a multicenter, retrospective clinical study

Multimodal AI for Predicting Survival Risk in critically ill children: a multicenter, retrospective clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093026
Enrollment
Unknown
Registered
2024-11-27
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critically ill children

Interventions

Observation group:None

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: ? Infants admitted to NICU and PICU from January 1, 2018, to March 31, 2023; ? Age <18 years, any gender; ? Patients admitted and underwent routine blood tests using Mindray Medical's five-classification blood cell analyzer (including BC6000, BC6000PLUS, BC6800PLUS, BC7500 series), with the instrument or computer system retaining relatively complete multimodal blood cell data; ? Accessible and detailed clinical medical records relevant to this study; ? For patients readmitted to NICU or PICU multiple times, each readmission is considered as a new case due to varying conditions, etiology, and outcomes.

Exclusion criteria

Exclusion criteria: 1. Cardiac arrest or death within 24 hours of admission; 2. Children with blood diseases, including iron deficiency anemia, megaloblastic anemia, hereditary spherocytosis, erythrocyte glucose-6-phosphate dehydrogenase deficiency, thalassemia, autoimmune hemolytic anemia, aplastic anemia, immune thrombocytopenia, acute lymphoblastic leukemia, acute non-lymphocytic leukemia, multiple myeloma, Henoch-Schonlein purpura, myelodysplastic syndrome, etc.; 3. Children with hereditary metabolic diseases, including galactosemia, mucopolysaccharidosis, glycogen storage disease, phenylketonuria, albinism, melaturia, hypoxanthine-guanine phosphoribosyltransferase deficiency, xeroderma pigmentosum, Gaucher disease, Tay-Sachs disease, etc.; 4. Children with chromosomal diseases, including Down syndrome, trisomy 18, etc.; 5. Children with congenital immunodeficiency diseases; 6. Children transfused with blood products within half a year, including transfusion of component blood, human immunoglobulin, etc.; 7. Children with a hospital stay of < 24 hours; 8. Non-critically ill children who are temporarily transitioning to the NICU or PICU due to bed problems in other wards.

Design outcomes

Primary

MeasureTime frame
death;sepsis;

Secondary

MeasureTime frame
MODS;DIC;chronic lung disease or acute respiratory distress syndrome in children;shock;time of death;PICU or NICU hospitalization duration;Brain injury or neurological complications;

Countries

China

Contacts

Public ContactHe yan

Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University

yanhe@i.smu.edu.cn+86 138 2442 0986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026